Switching to an alternative ALK-inhibitor after alectinib-induced pneumonitis resulted in resolution of this adverse event-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Switching to an alternative ALK-inhibitor after alectinib-induced pneumonitis resulted in resolution of this adverse event

Published:2020-12 Issue: Volume:2 Page:100023
ISSN:2666-6219
Container-title:Current Problems in Cancer: Case Reports
language:en
Short-container-title:Current Problems in Cancer: Case Reports

Author:

Bryson Evan,Ramalingam Suresh,Beardslee Tyler

Publisher

Elsevier BV

Subject

General Medicine

Reference17 articles.

1. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future;Chan;Transl. Lung Cancer Res.,2015

2. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer;Peters;N. Engl. J. Med.,2017

3. National Comprehensive CancerNetwork Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 3.2020, February 11, 2020.

4. Xalkori (crizotinib)[Prescribing Information]. New York, NY; Pfizer, Inc.; 2016

5. Zykadia (ceritinib)[Prescribing Information]. East Hanover, NJ; Novartis Pharmaceuticals Corporation; 2019

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Complications following novel therapies for non‐small cell lung cancer;Journal of Internal Medicine;2022-01-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP